Literature DB >> 22946657

Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function.

D Wootten1, H Lindmark, M Kadmiel, H Willcockson, K M Caron, J Barwell, T Drmota, D R Poyner.   

Abstract

BACKGROUND AND
PURPOSE: Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor (GLP-1 receptor), the human vasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC(2)) and the type 1 corticotrophin releasing factor receptor (CRF(1)) has been examined. EXPERIMENTAL APPROACH: GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells. Cell surface expression of RAMPs and GPCRs was examined by ELISA. Where there was evidence for interactions, agonist-stimulated cAMP production, Ca(2+) mobilization and GTPγS binding to G(s), G(i), G(12) and G(q) were examined. The ability of CRF to stimulate adrenal corticotrophic hormone release in Ramp2(+/-) mice was assessed. KEY
RESULTS: The GLP-1 receptor failed to enhance the cell surface expression of any RAMP. VPAC(2) enhanced the cell surface expression of all three RAMPs. CRF(1) enhanced the cell surface expression of RAMP2; the cell surface expression of CRF(1) was also increased. There was no effect on agonist-stimulated cAMP production. However, there was enhanced G-protein coupling in a receptor and agonist-dependent manner. The CRF(1) : RAMP2 complex resulted in enhanced elevation of intracellular calcium to CRF and urocortin 1 but not sauvagine. In Ramp2(+/-) mice, there was a loss of responsiveness to CRF. CONCLUSIONS AND IMPLICATIONS: The VPAC(2) and CRF(1) receptors interact with RAMPs. This modulates G-protein coupling in an agonist-specific manner. For CRF(1), coupling to RAMP2 may be of physiological significance.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22946657      PMCID: PMC3631373          DOI: 10.1111/j.1476-5381.2012.02202.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia.

Authors:  Mikael Knutsson; Lars Edvinsson
Journal:  Neuroreport       Date:  2002-03-25       Impact factor: 1.837

Review 2.  International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors.

Authors:  David R Poyner; Patrick M Sexton; Ian Marshall; David M Smith; Remi Quirion; Walter Born; Roman Muff; Jan A Fischer; Steven M Foord
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

Review 3.  Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction.

Authors:  Dimitris K Grammatopoulos
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1.

Authors:  A Rühmann; I Bonk; A K Köpke
Journal:  Peptides       Date:  1999-11       Impact factor: 3.750

5.  Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat.

Authors:  K R Oliver; S A Kane; C A Salvatore; J J Mallee; A M Kinsey; K S Koblan; N Keyvan-Fouladi; R P Heavens; A Wainwright; M Jacobson; I M Dickerson; R G Hill
Journal:  Eur J Neurosci       Date:  2001-08       Impact factor: 3.386

6.  Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins.

Authors:  D K Grammatopoulos; H S Randeva; M A Levine; E S Katsanou; E W Hillhouse
Journal:  Mol Endocrinol       Date:  2000-12

7.  Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.

Authors:  F M Dautzenberg; G Py-Lang; J Higelin; C Fischer; M B Wright; G Huber
Journal:  J Pharmacol Exp Ther       Date:  2001-01       Impact factor: 4.030

8.  A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.

Authors:  Manami Tsutsumi; Thomas H Claus; Yin Liang; Yaxin Li; Ling Yang; Jian Zhu; Fernando Dela Cruz; Xianbu Peng; Hongxing Chen; Stephanie L Yung; Sarah Hamren; James N Livingston; Clark Q Pan
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

9.  Novel receptor partners and function of receptor activity-modifying proteins.

Authors:  Arthur Christopoulos; George Christopoulos; Maria Morfis; Madhara Udawela; Marc Laburthe; Alain Couvineau; Kenji Kuwasako; Nanda Tilakaratne; Patrick M Sexton
Journal:  J Biol Chem       Date:  2002-11-21       Impact factor: 5.157

10.  Immunohistochemical localization of calcitonin receptor-like receptor and receptor activity-modifying proteins in the human cerebral vasculature.

Authors:  Kevin R Oliver; Anna Wainwright; Lars Edvinsson; John D Pickard; Raymond G Hill
Journal:  J Cereb Blood Flow Metab       Date:  2002-05       Impact factor: 6.200

View more
  35 in total

1.  PACAP receptor pharmacology and agonist bias: analysis in primary neurons and glia from the trigeminal ganglia and transfected cells.

Authors:  C S Walker; T Sundrum; D L Hay
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

Review 2.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 3.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 4.  Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Authors:  Ya-Xiong Tao; P Michael Conn
Journal:  Endocr Rev       Date:  2014-03-24       Impact factor: 19.871

Review 5.  Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine.

Authors:  Tahlia Sundrum; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-10-25       Impact factor: 8.739

6.  RAMP3 determines rapid recycling of atypical chemokine receptor-3 for guided angiogenesis.

Authors:  Duncan I Mackie; Natalie R Nielsen; Matthew Harris; Smriti Singh; Reema B Davis; Danica Dy; Graham Ladds; Kathleen M Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-11       Impact factor: 11.205

Review 7.  Roles of CLR/RAMP receptor signaling in reproduction and development.

Authors:  Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  Curr Protein Pept Sci       Date:  2013-08       Impact factor: 3.272

8.  Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.

Authors:  Marilyn H Perrin; Laura A Tan; Joan M Vaughan; Kathy A Lewis; Cynthia J Donaldson; Charleen Miller; Judit Erchegyi; Jean E Rivier; Paul E Sawchenko
Journal:  J Pharmacol Exp Ther       Date:  2015-03-03       Impact factor: 4.030

Review 9.  The expanding repertoire of receptor activity modifying protein (RAMP) function.

Authors:  Klara R Klein; Brooke C Matson; Kathleen M Caron
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-01-06       Impact factor: 8.250

10.  RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.

Authors:  Monica Logan; Philip D Anderson; Shahrazad T Saab; Omar Hameed; Sarki A Abdulkadir
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.